Your browser is no longer supported. Please, upgrade your browser.
Settings
DCPH [NASD]
Deciphera Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-4.49 Insider Own0.30% Shs Outstand57.75M Perf Week6.00%
Market Cap2.01B Forward P/E- EPS next Y-3.22 Insider Trans-30.22% Shs Float40.91M Perf Month3.73%
Income-255.00M PEG- EPS next Q-1.15 Inst Own76.60% Short Float7.99% Perf Quarter-14.96%
Sales67.20M P/S29.94 EPS this Y-6.50% Inst Trans1.11% Short Ratio7.69 Perf Half Y-35.06%
Book/sh8.71 P/B4.12 EPS next Y27.50% ROA-39.50% Target Price- Perf Year-38.81%
Cash/sh8.95 P/C4.01 EPS next 5Y21.00% ROE-45.60% 52W Range31.77 - 68.40 Perf YTD-37.13%
Dividend- P/FCF- EPS past 5Y-49.20% ROI-49.90% 52W High-46.55% Beta1.51
Dividend %- Quick Ratio8.50 Sales past 5Y- Gross Margin99.30% 52W Low15.08% ATR1.41
Employees350 Current Ratio8.60 Sales Q/Q40474.20% Oper. Margin- RSI (14)56.08 Volatility3.39% 3.68%
OptionableYes Debt/Eq0.00 EPS Q/Q21.90% Profit Margin- Rel Volume0.30 Prev Close35.88
ShortableYes LT Debt/Eq0.00 EarningsMay 04 AMC Payout- Avg Volume425.09K Price36.56
Recom1.80 SMA208.07% SMA50-5.90% SMA200-25.29% Volume69,511 Change1.90%
Mar-31-21Initiated Credit Suisse Outperform $78
Feb-10-21Upgrade SVB Leerink Mkt Perform → Outperform $70
Dec-03-20Initiated Stifel Buy $75
Sep-14-20Resumed JP Morgan Neutral $52
May-07-20Downgrade Nomura Buy → Neutral $84 → $60
Mar-04-20Initiated Barclays Overweight $70
Dec-20-19Reiterated Jefferies Buy $53 → $77
Oct-29-19Upgrade SVB Leerink Underperform → Mkt Perform $29 → $34
Oct-22-19Initiated JMP Securities Mkt Outperform
Oct-03-19Initiated H.C. Wainwright Buy $60
Sep-30-19Initiated Jefferies Buy $47
Jul-18-19Initiated Deutsche Bank Buy $42
Dec-31-18Upgrade B. Riley FBR Neutral → Buy $27 → $34
Sep-25-18Initiated Leerink Partners Underperform
Aug-29-18Initiated Raymond James Outperform $47
Jul-05-18Initiated SunTrust Buy
Jun-19-18Downgrade B. Riley FBR, Inc. Buy → Neutral $43
Feb-16-18Initiated B. Riley FBR, Inc. Buy $43
Oct-23-17Initiated Piper Jaffray Overweight $35
Oct-23-17Initiated Nomura Buy
Jun-08-21 03:16PM  
Jun-04-21 09:00AM  
Jun-03-21 11:31AM  
May-27-21 07:00AM  
May-05-21 11:54AM  
07:30AM  
May-04-21 05:55PM  
04:22PM  
02:30PM  
Apr-27-21 07:00AM  
Apr-20-21 03:05AM  
Apr-08-21 02:01PM  
Mar-31-21 04:57AM  
Mar-22-21 07:57AM  
Mar-02-21 07:00AM  
Feb-18-21 07:00AM  
Feb-10-21 11:29PM  
10:21AM  
10:05AM  
Feb-09-21 10:00PM  
05:31PM  
05:15PM  
04:01PM  
02:30PM  
Feb-08-21 09:58AM  
12:35AM  
Feb-04-21 07:00AM  
Feb-02-21 07:00AM  
Jan-11-21 07:00AM  
Jan-05-21 07:23AM  
Dec-20-20 10:04PM  
Dec-18-20 12:14PM  
Dec-01-20 10:04AM  
Nov-30-20 07:00AM  
Nov-24-20 04:01PM  
Nov-23-20 07:00AM  
Nov-11-20 07:01AM  
07:00AM  
Nov-10-20 07:00AM  
05:29AM  
Nov-09-20 10:18AM  
Nov-06-20 10:31PM  
Nov-05-20 04:01PM  
02:45PM  
Oct-28-20 07:00AM  
Sep-22-20 04:23PM  
Sep-20-20 09:12AM  
Sep-18-20 07:00AM  
Sep-17-20 07:00AM  
Sep-15-20 12:48AM  
Aug-17-20 04:30PM  
Aug-06-20 08:40AM  
Aug-05-20 08:01AM  
Aug-04-20 06:25PM  
04:05PM  
Jul-29-20 07:00AM  
Jul-20-20 10:39AM  
07:30AM  
Jul-14-20 07:00AM  
Jul-12-20 08:15PM  
Jul-09-20 08:01AM  
Jul-02-20 04:01PM  
Jun-22-20 07:00AM  
Jun-17-20 07:36PM  
Jun-11-20 07:00AM  
Jun-08-20 07:30AM  
02:56AM  
Jun-03-20 07:11AM  
May-29-20 08:05AM  
08:00AM  
May-27-20 07:00AM  
May-26-20 07:06AM  
May-23-20 07:34AM  
May-18-20 04:16PM  
12:22PM  
06:15AM  
May-15-20 06:34PM  
May-12-20 06:53AM  
May-08-20 09:25AM  
May-06-20 12:01PM  
May-05-20 06:35PM  
04:01PM  
May-04-20 01:36PM  
08:45AM  
Apr-28-20 11:19AM  
07:00AM  
Apr-23-20 09:06AM  
Mar-28-20 09:10PM  
Mar-09-20 05:15PM  
04:01PM  
02:30PM  
Mar-02-20 07:00AM  
Feb-20-20 07:00AM  
Feb-19-20 04:01PM  
Feb-13-20 10:12PM  
01:36PM  
10:31AM  
08:05AM  
Feb-12-20 04:14PM  
04:01PM  
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing immunokinase inhibitors comprising vimseltinib (DCC-3014) that is in Phase 1b/2 clinical trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase 1b/2 clinical trial to treat metastatic solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, it is developing DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. The company serves in the United States and Europe. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bristol James ArthurDirectorApr 20Option Exercise3.951,7006,7151,700Apr 21 04:30 PM
Bristol James ArthurDirectorApr 20Sale45.601,70077,5140Apr 21 04:30 PM
Bristol James ArthurDirectorApr 19Option Exercise3.955,30020,9355,300Apr 21 04:30 PM
Bristol James ArthurDirectorApr 19Sale46.265,300245,1800Apr 21 04:30 PM
Bristol James ArthurDirectorApr 12Option Exercise3.9514,70058,06514,700Apr 14 04:00 PM
Bristol James ArthurDirectorApr 12Sale43.8414,700644,4110Apr 14 04:00 PM
Taylor Michael DouglasDirectorApr 01Option Exercise1.898,00015,1208,000Apr 06 06:00 AM
Taylor Michael DouglasDirectorApr 01Sale45.578,000364,5720Apr 06 06:00 AM
Taylor Michael DouglasDirectorMar 01Option Exercise1.898,00015,1208,000Mar 03 04:00 PM
Taylor Michael DouglasDirectorMar 01Sale44.048,000352,3070Mar 03 04:00 PM
Sherman Matthew LEVP & Chief Medical OfficerFeb 16Sale48.871326,45137,286Feb 18 07:00 PM
Flynn Daniel LeeChief Scientific OfficerFeb 16Sale48.8750824,8266,532Feb 18 07:00 PM
Kelly Thomas PatrickChief Financial OfficerFeb 16Sale48.8752425,6086,516Feb 18 07:00 PM
Taylor Michael DouglasDirectorFeb 01Option Exercise1.898,00015,1208,000Feb 03 04:00 PM
Taylor Michael DouglasDirectorFeb 01Sale45.238,000361,8720Feb 03 04:00 PM
Hoerter Steven L.President and CEOJan 21Option Exercise25.401,07827,38143,845Jan 25 05:00 PM
Bristol James ArthurDirectorJan 15Option Exercise3.957,00027,6507,000Jan 20 04:00 PM
Bristol James ArthurDirectorJan 15Sale50.297,000352,0390Jan 20 04:00 PM
Taylor Michael DouglasDirectorJan 04Option Exercise1.8919,00035,91019,000Jan 06 04:10 PM
Taylor Michael DouglasDirectorJan 04Sale56.4519,0001,072,4970Jan 06 04:10 PM
Sherman Matthew LEVP & Chief Medical OfficerDec 09Option Exercise34.432077,12737,418Dec 11 04:10 PM
Taylor Michael DouglasDirectorDec 01Option Exercise1.8919,00035,91019,000Dec 03 04:15 PM
Taylor Michael DouglasDirectorDec 01Sale60.9019,0001,157,1420Dec 03 04:15 PM
Sherman Matthew LEVP & Chief Medical OfficerNov 16Option Exercise34.432,69792,85837,211Nov 18 07:31 PM
Taylor Michael DouglasDirectorNov 04Option Exercise1.8915,00028,35015,000Nov 06 04:00 PM
Taylor Michael DouglasDirectorNov 04Sale64.8015,000971,9870Nov 06 04:00 PM
Taylor Michael DouglasDirectorNov 02Option Exercise1.8923,31544,06523,315Nov 04 04:10 PM
Taylor Michael DouglasDirectorNov 02Sale57.6423,3151,343,9260Nov 04 04:10 PM
Bristol James ArthurDirectorOct 09Option Exercise1.8923,54144,49223,541Oct 13 04:20 PM
Bristol James ArthurDirectorOct 09Sale53.5723,5411,261,0690Oct 13 04:20 PM
Taylor Michael DouglasDirectorOct 01Option Exercise1.89125,000236,250125,000Oct 05 04:00 PM
Taylor Michael DouglasDirectorOct 01Sale51.60125,0006,450,4840Oct 05 04:00 PM
Kelly Thomas PatrickChief Financial OfficerSep 14Option Exercise1.893,0005,67010,040Sep 16 04:00 PM
Kelly Thomas PatrickChief Financial OfficerSep 14Sale50.013,000150,0367,040Sep 16 04:00 PM
Kelly Thomas PatrickChief Financial OfficerSep 10Option Exercise1.893,0005,67010,040Sep 10 08:29 PM
Kelly Thomas PatrickChief Financial OfficerSep 10Sale47.713,000143,1267,040Sep 10 08:29 PM
Kelly Thomas PatrickChief Financial OfficerSep 08Option Exercise1.896,00011,34013,040Sep 10 08:29 PM
Kelly Thomas PatrickChief Financial OfficerSep 08Sale45.496,000272,9297,040Sep 10 08:29 PM
Hoerter Steven L.President and CEOAug 20Option Exercise25.401874,75042,767Aug 24 04:00 PM
Flynn Daniel LeeChief Scientific OfficerAug 10Option Exercise1.899,02917,065237,475Aug 12 04:00 PM
Flynn Daniel LeeChief Scientific OfficerJul 22Option Exercise1.89130,000245,700228,446Jul 24 04:00 PM
Hoerter Steven L.President and CEOJul 20Option Exercise25.401884,77542,580Jul 22 04:00 PM
Bristol James ArthurDirectorJul 09Option Exercise1.8923,54144,49223,541Jul 13 04:11 PM
Bristol James ArthurDirectorJul 09Sale54.9923,5411,294,6340Jul 13 04:11 PM
Taylor Michael DouglasDirectorJul 06Option Exercise1.8927,54452,05827,544Jul 06 06:16 PM
Taylor Michael DouglasDirectorJul 06Sale55.2227,5441,520,8730Jul 06 06:16 PM
Taylor Michael DouglasDirectorJul 02Option Exercise1.8948,24591,18348,245Jul 06 06:16 PM
Taylor Michael DouglasDirectorJul 02Sale56.6948,2452,734,9650Jul 06 06:16 PM
Taylor Michael DouglasDirectorJul 01Option Exercise1.8949,21193,00949,211Jul 06 06:16 PM
Taylor Michael DouglasDirectorJul 01Sale58.8749,2112,896,8890Jul 06 06:16 PM
Hoerter Steven L.President and CEOJun 18Option Exercise25.401874,75042,392Jun 19 04:00 PM